2021
DOI: 10.20945/2359-3997000000385
|View full text |Cite
|
Sign up to set email alerts
|

Use of aromatase inhibitors in patients with breast cancer is associated with deterioration of bone microarchitecture and density

Abstract: Objective: To evaluate changes in bone density and architecture in postmenopausal women with breast cancer (BC) and use of aromatase inhibitor (AI). Subjects and methods: Thirty-four postmenopausal women with BC, without bone metastasis, renal function impairment and who were not receiving bone-active drugs were selected from a population of 523 outpatients treated for BC. According to the presence of hormonal receptors, HER2 and Ki67, seventeen had positive hormonal receptors and received anastrozole (AI grou… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…In this context, the Fracture Risk Assessment Tool (FRAX) represents an important advance in the assessment of this risk [6]. The few studies discussing the use of FRAX in women with breast cancer have concluded that FRAX scores stratify fracture risk equally well between women undergoing endocrine therapy with AI and non-users, and that all patients who start treatment with AI should have their fracture risk assessed [9,10].…”
Section: Introductionmentioning
confidence: 99%
“…In this context, the Fracture Risk Assessment Tool (FRAX) represents an important advance in the assessment of this risk [6]. The few studies discussing the use of FRAX in women with breast cancer have concluded that FRAX scores stratify fracture risk equally well between women undergoing endocrine therapy with AI and non-users, and that all patients who start treatment with AI should have their fracture risk assessed [9,10].…”
Section: Introductionmentioning
confidence: 99%